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The cancer genomics revolution has rapidly expanded the inventory of somatic mutations characterizing human malignancies,
highlighting a previously underappreciated extent of molecular variability between and within patients. Also in breast cancer,
the most commonly diagnosed malignancy in women, this heterogeneity complicates the understanding of the stepwise
sequence of pathogenic events and the design of effective and long-lasting target therapies. To disentangle this complexity
and pinpoint which molecular perturbations are crucial to hijack the cellular machinery and lead to tumorigenesis and drug
resistance, functional studies are needed in model systems that faithfully and comprehensively recapitulate all the salient
aspects of their cognate human counterparts. Mouse models of breast cancer have been instrumental for the study of tumor
initiation and drug response but also involve cost and time limitations that represent serious bottlenecks in translational
research. To keep pace with the overwhelming amount of hypotheses that warrant in vivo testing, continuous refinement of
current breast cancer models and implementation of new technologies is crucial. In this review, we summarize the current state
of the art in modeling human breast cancer in mice, and we put forward our vision for future developments.
Breast cancer is the most commonly diagnosed invasive
cancer worldwide, with more than 1.6 million new cases
each year. Rather than a single disease, it represents a
spectrum of malignancies, encompassing several distinct
biological entities and subtypes, each associated with spe-
cific histopathological and molecular characteristics, re-
sponses to therapy, and clinical outcomes. Multiple
taxonomies have been developed to divide breast cancer
cases into different categories. Histopathological classifi-
cation comprises several morphological and immunohis-
tochemical phenotypes that can be further divided into
different grades. Among the various morphologies, ad-
vanced mammary tumors mostly fall into the class of
invasive ductal carcinomas (IDCs), followed by invasive
lobular carcinomas (ILCs). Molecular classification
based on gene expression patterns distinguishes five ma-
jor subtypes of breast cancer: luminal A and B, ErbB2þ,
basal-like, and claudin-low (Perou et al. 2000). Although
these distinctions have proven useful for clinical decision-
making, there are limitations in predicting disease prog-
nosis and response to therapy. For example, a recent pro-
spective, randomized phase III study showed that nearly
half of the women with early breast cancer who are at high
risk based on standard clinicopathological parameters
might not require adjuvant chemotherapy (Cardoso et al.
2016). The additional use of a 70-gene expression signa-
ture may help to identify breast cancer patients who do not
require adjuvant chemotherapy, but the identification of
molecular signatures that reliably predict chemotherapy
response remains elusive. Moreover, sequencing studies
have shown that even within the same molecular subtype
an extreme heterogeneity in the mutational landscape ex-
ists, which may account for discrepancies in prognosis and
therapy response between different patients (Cancer Ge-
nome Atlas Network 2012; Stephens et al. 2012; Nik-
Zainal et al. 2016). Another complicating factor is intra-
tumoral heterogeneity. Individual tumors are mosaics of
multiple clones of neoplastic cells, each characterized by a
distinct genetic makeup and differential responses to the
selective pressures to which they are exposed, making the
tumor mass not static but continuously shaped by a
branching evolutionary process resembling Darwinian
evolution. Distinguishing causal disease variants (driver
mutations) from background alterations (passenger muta-
tions) is a major goal in breast cancer research, as it can
pinpoint evolutionary conserved processes that mammary
tumor cells apply during stepwise transformation and to
which they might be addicted. To exploit these potential
Achilles’ heels, we require a comprehensive knowledge of
how these signaling networks physiologically function,
how they become aberrant, and how they can be directly
or indirectly disrupted.
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Given this complexity, genetically engineered mouse
models (GEMMs) of breast cancer, together with patient-
derived tumor xenografts (PDXs) and GEMM-derived
tumor allografts, have proven valuable resources for
deepening our understanding of how mammary tumors
initiate, progress, metastasize, and respond to therapy in a
physiologically relevant in vivo setting (Vargo-Gogola
and Rosen 2007). These mouse models are increasingly
being used in longitudinal preclinical studies for transla-
tion of novel therapies to clinical testing. Moreover,
GEMMs provide unique opportunities to infer cause–
effect relationships on de novo induced malignancies
growing in intact organisms, rather than correlative ob-
servations on end-stage patient tumor samples.
Over the past 15 years, our research has been focused
on the generation and characterization of mouse models
for two breast cancer subtypes: ILCs and basal-like IDCs.
To achieve this, we engineered a number of tumor-spe-
cific driver mutations in the relevant target cells of mouse
models, recapitulating the key dependencies of the result-
ing lesions to the corresponding deranged signaling path-
ways. In this review, we will discuss how these models
can be used for functional dissection of tumorigenic cas-
cades, unraveling new therapeutic vulnerabilities and
mechanisms of therapy resistance—in particular, in light
of the advent of new technologies such as clustered reg-
ularly interspersed short palindromic repeat (CRISPR)–
Cas9 gene editing, which are opening new avenues in
breast cancer modeling in mice.
INVASIVE LOBULAR BREAST CARCINOMA
(ILC) MODELS
ILC accounts for 8%–14% of all breast cancer cases
and is hallmarked at the morphological level by tumor
cells growing in single “Indian files” within a dense fi-
brous stroma. This phenotype can be explained at the
molecular level by loss of integrity of cell adherens junc-
tions because of mutations or methylation of the CDH1
gene, which encodes the transmembrane protein E-cad-
herin (Martinez and Azzopardi 1979; Borst and Ingold
1993; Moll et al. 1993; Vos et al. 1997; Droufakou et al.
2001). To our surprise, we found that mammary gland–
specific Cre-mediated inactivation of Cdh1 alleles in
mice was insufficient to induce mammary tumors, prob-
ably because normal cells undergo apoptosis and are
counterselected when E-cadherin is lost (Boussadia
et al. 2002; Derksen et al. 2006, 2011). This prompted
us to investigate which cooperating oncogenic events are
required for malignant transformation of E-cadherin-de-
ficient mammary epithelial cells. We have found that
multifocal ILC formation is promoted by dual mamma-
ry-specific loss of E-cadherin and p53 (Derksen et al.
2006, 2011) or E-cadherin and PTEN (phosphatase and
tensin homolog) (Boelens et al. 2016), with tumor archi-
tecture and molecular profiles closely resembling their
human ILC counterparts (Table 1). However, it remains
elusive which biological processes are rescued by code-
pletion of E-cadherin with one of these factors. To identify
novel candidate cancer genes and networks that collabo-
rate with E-cadherin loss in mammary tumorigenesis, we
used the Sleeping Beauty (SB) transposon system (Collier
et al. 2005; Dupuy et al. 2005) to perform an insertional
mutagenesis screen in WAPcre;Cdh1F/F mice (SM Kas,
J de Ruiter, K Schipper, et al., in prep.). Retrieval of re-
current integrations in SB-induced WAPcre;Cdh1F/F
mammary tumors identified common insertion sites in
several genes, some known to be mutated in human ILC,
suggesting that mutagenesis of these genes leads to malig-
nant transformation. Moreover, analysis of enriched tar-
geted pathways and mutuallyexclusive insertions revealed
the regulation of the actin cytoskeleton as a completely
novel oncogenic pathway in both mouse and human ILC.
Furthermore, recent genomic studies on collections of
human ILCs have unveiled that, in addition to somatic
inactivation of E-cadherin, activation of phosphoinositide
3-kinase (PI3K)/AKT signaling appears to be a common
event in this breast cancer subtype (Ciriello et al. 2015;
Desmedt et al. 2016; Michaut et al. 2016). To validate
these findings, we developed GEMMs of ILC that com-
bine mammary gland–specific ablation of E-cadherin and
activation of different oncogenic Pik3ca or Akt mutants
(MHAM van Miltenburg, et al., in prep.). To rapidly gen-
erate breast cancer models carrying these allelic variants,
we used a novel strategy for fast-track production of
GEMMs, called GEMM-ESC, which is based on Flp-
recombinase-mediated introduction of additional mutant
alleles into the Col1a1 locus of embryonic stem cells
(ESCs) derived from existing GEMMs (Huijbers et al.
2014). Interestingly, the resulting mice showed rapid de-
velopment of tumors with strong resemblance to human
ILC in terms of morphology, gene expression, and inva-
siveness, on which we are now testing a panel of antican-
Table 1. Characteristics of human ILC and BRCA1-associated
breast cancer and the corresponding GEMMs developed in our
laboratory
Invasive lobular
carcinoma Human
WAPcre;Cdh1F/F;PtenF/F
mouse model
Morphology Lobular Lobular
Invasive Yes Yes
Grade Low Low
Mitotic index Low Low
ER expression Yes Yes
Molecular subtype Luminal Luminal
Collagen deposition Yes Yes
Stroma-rich Yes Yes
BRCA1-associated
breast cancer Human
K14cre;Brca1F/F;p53F/F
mouse model
Morphology Ductal Ductal
Invasive Yes Yes
Grade High High
Mitotic index High High
ER/PR expression No No
Molecular subtype Basal-like Basal-like
Genomically
instable
Yes Yes
HR-deficient Yes Yes
ILC, invasive lobular carcinoma; BRCA1, breast cancer gene 1;
GEMMs, genetically engineered mouse models; ER, estrogen receptor;
PR, progesterone receptor; HR, homologous recombination.
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cer therapeutics to identify promising genotype-specific
drug sensitivities.
BASAL-LIKE BREAST CANCER MODELS
Basal-like breast cancers represent a heterogeneous
class of malignancies with poor clinical outcome that
accounts in total for 10%–15% of all breast cancer cases
(Perou et al. 2000; Badve et al. 2011). The majority of
basal-like tumors lack expression of estrogen receptor
(ER), progesterone receptor (PR), and human epidermal
growth factor receptor 2 (HER2) and are therefore re-
ferred to as triple-negative breast cancers. These tumors
are not targetable with hormonal therapy or HER2 inhib-
itors, which leaves clinicians with only few effective op-
tions for therapeutic intervention.
Approximately 50% of basal-like breast cancers dis-
play a dysfunctional BRCA pathway because of germline
or somatic mutations in BRCA1/2 or BRCA1 promoter
hypermethylation (Cancer Genome Atlas Network 2012;
Nik-Zainal et al. 2016). Also a fraction of non-basal-like
tumors are BRCA-deficient, mostly because of germline
mutations in BRCA2. As these genes are crucial in the
error-free repair of DNA double-strand breaks (DSBs) by
homologous recombination (HR), BRCA defects are as-
sociated with chromosomal instability and hypersensitiv-
ity to DNA DSB-inducing drugs such as alkylating
agents, poly ADP ribose polymerase inhibitors (PARPi),
and radiotherapy (Jaspers et al. 2009; Bouwman and
Jonkers 2012; M Barazas, et al., in prep.). However,
drug resistance mechanisms have been described in
both clinical and preclinical studies of BRCA-associated
tumors, posing serious concerns, as no other therapies are
currently available for relapsing patients.
To study tumorigenesis and drug resistance mecha-
nisms, we developed several conditional mouse models
for BRCA1- and BRCA2-associated breast cancer (Evers
and Jonkers 2006; Bouwman and Jonkers 2008). In our
K14cre;Brca1F/F;p53F/F (KB1P) and K14cre;Brca2F/F;
p53F/F (KB2P) models, mammary inactivation of Brca1/
2 is accompanied by loss of p53, as mutations in this
tumor suppressor frequently co-occur with BRCA1/2
mutations in breast cancer (Jonkers et al. 2001; Liu
et al. 2007). These mice develop mammary tumors after
a latency period of 6–8 mo, suggesting that additional
mutations are required for tumorigenesis (Table 1). How-
ever, in contrast to ILC, in which point mutations are the
most common somatic alterations, BRCA-mutated breast
cancers are characterized by complex patterns of DNA
copy number aberrations (CNAs), including transloca-
tions and gains/losses of entire chromosome arms (Vol-
lebergh et al. 2012). Using cross-species oncogenomics,
we identified MYC amplification and RB1 loss as recur-
rent CNAs in both mouse and human BRCA1/2-mutated
breast cancers (Holstege et al. 2010). Exploiting the
GEMM-ESC strategy, we could model conditional over-
expression of MYC in our WAPcre;Brca1F/F;p53F/F
(WB1P) mouse model and found that mammary tumor
development was indeed strongly accelerated compared
to the original line (L Henneman, et al., in prep.). More-
over, we observed that the number of CNAs in WB1P-
MYC tumors was markedly reduced compared to WB1P
tumors, showing only few recurrent CNAs that most like-
ly harbor additional cancer drivers that collaborate with
MYC overexpression and loss of BRCA1/p53 in breast
tumorigenesis. We are currently performing cross-spe-
cies comparisons of the recurrent CNAs in WB1P-
MYC tumors with CNA profiles from human breast can-
cers to identify candidate cancer genes, which will be
validated in the WB1P-MYC model. We believe that
this iterative CNA profiling approach in progressively
complex GEMMs will be instrumental for deciphering
the key driver events in BRCA1-associated breast cancer
and for uncovering novel therapeutic vulnerabilities.
PRECLINICAL TRIALS IN BRCA-
ASSOCIATED BREAST CANCER MODELS
Although phase-I and -II clinical trials are mostly car-
ried out in heavily pretreated volunteer patients who suf-
fer from end-stage metastatic cancer, mouse models
provide the opportunity to initiate treatment on naı¨ve tu-
mors in a clinically relevant in vivo setting. Treatment of
mammary tumor-bearing KB1P mice with a panel of
DSB-inducing agents showed heterogeneous responses
between individual tumors but also marked differences
in tumors treated with doxorubicin or docetaxel and those
treated with cisplatin (Rottenberg et al. 2007). Although
KB1P tumors eventually developed resistance to doxo-
rubicin and docetaxel, no acquired resistance was ob-
served for cisplatin. Even though these tumors could
never be completely eradicated by maximum tolerated
dose concentrations of cisplatin, the relapsing tumors re-
mained responsive to subsequent treatments, resulting in
a typical sawtooth tumor response. A major breakthrough
came when it was found that spontaneous KB1P and
KB2P tumors could be orthotopically allografted in syn-
geneic mice while maintaining their genetic characteris-
tics and drug sensitivity profile. This approach reduced
the time to produce cohorts of tumor-bearing mice from
7–9 mo to 4–6 wk, and enabled large-scale intervention
studies in which the response of a single donor to dif-
ferent chemotherapeutic strategies could be compared,
ruling out any intertumor heterogeneity (Fig. 1). Inter-
vention studies with the PARP inhibitor olaparib in
KB1P tumor allografts led to the development of carbo-
platin and olaparib switch-maintenance therapy for
BRCA1-mutated breast cancer (Rottenberg et al. 2008).
This preclinical concept was confirmed in a clinical trial
with olaparib maintenance therapy in BRCA-mutation
carriers with platinum-sensitive ovarian cancer (Leder-
mann et al. 2012, 2014) and eventually led to clinical
approval of olaparib (Deeks 2015). Similarly, interven-
tion studies in KB2P tumor allografts showed that al-
kylators such as nimustine could induce complete
tumor eradication (Evers et al. 2010). Eradication of
BRCA-mutated and BRCA-like cancer by high-dose al-
kylating chemotherapy was subsequently confirmed by
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retrospective analysis of data from clinical trials (Volle-
bergh et al. 2011, 2014; Schouten et al. 2015). These and
other studies illustrate the utility of GEMMs of human
cancer in translational cancer medicine.
PARPi RESISTANCE MECHANISMS IN BRCA-
ASSOCIATED BREAST CANCER MODELS
In addition to accelerating preclinical trials, the KB1P
and KB2P allograft platforms also enabled large-scale
induction of acquired resistance to a drug of choice and
subsequent identification of the underlying resistance
mechanisms. The power of this approach was demonstrat-
ed with the PARP inhibitor olaparib, which was described
to display selective toxicity against BRCA1/2-deficient
cells (Bryant et al. 2005; Farmer et al. 2005). Indeed,
KB1P tumor allografts initially responded well to treat-
ment but eventually relapsed and developed stable resis-
tance (Rottenberg et al. 2008). This has provided a
valuable collection of matched treatment-naı¨ve and treat-
ment-resistant tumors, which could be analyzed using
next-generation sequencing or (phospho)-proteomics,
thereby taking advantage of the clean genetic background
of inbred mice and the known genetic profile of treat-
ment-naı¨ve tumors. We found that Abcb1a and Abcb1b,
encoding P-glycoprotein (P-gp) efflux pumps, were up-
regulated in resistant tumors and we confirmed that P-gp
played an important role in mediating export of olaparib
from tumor cells (Fig. 2A; Rottenberg et al. 2008). Re-
sistance could be reversed when P-gp-mediated drug ef-
flux was inhibited by coadministration of tariquidar.
Although the clinical relevance of P-gp up-regulation as
cause of drug resistance remains controversial (Amiri-
Kordestani et al. 2012), expression of MDR1, the human
counterpart of Abcb1, was recently found to be inversely
correlated to olaparib response in human ovarian cancer
cells (Vaidyanathan et al. 2016). Such increased expres-
sion may result from complex genomic rearrangements
that fuse a distant promoter to the MDR1 gene and there-
by bypass the MDR1 promoter methylation (Patch et al.
2015). The case of P-gp shows that a thorough mechanis-
tic understanding is instrumental to combat resistant tu-
mors—for example, by coadministration of tariquidar or
by switching treatment to chemotherapeutics that are poor
substrates for P-gp (Jaspers et al. 2013).
To dissect P-gp-independent mechanisms of PARPi
resistance, the KB1P mouse model was refined through
germline genetic deletion of Mdr1 resulting in the
K14cre;Brca1F/F;p53F/F;Mdr1a/b2/2 (KB1PM) mod-
el (Jaspers et al. 2013). Alternatively, KB1P tumors were
treated with the PARP inhibitor AZD2461, which is a
poor substrate for P-gp (Oplustil O’Connor et al. 2016).
PARPi resistance developed in these models despite the
exclusion of P-gp-related mechanisms. To identify the
underlying resistance mechanisms, next-generation se-
quencing data from treatment-naı¨ve and PARPi-resistant
tumors were combined with data from unbiased function-
al genetic screens in vitro. Through an insertional muta-
genesis screen in conditional BRCA1-knockout mouse
ESCs, we found that loss of 53BP1 rescues the prolifer-
ation defect, HR deficiency, and PARPi hypersensitivity
of BRCA1-deficient cells by enhancing DSB end resec-
tion (Fig. 2B; Bouwman et al. 2010). This work from our
laboratory and similar studies from the Nussenzweig lab-
oratory (Bunting et al. 2010) have led to novel mechanis-
tic insights in DSB repair and to date several downstream
effector proteins of 53BP1 have been shown to suppress
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Figure 1. Large-scale intervention studies using breast cancer gene (BRCA)-deficient orthotopic allografts. Spontaneous tumors
develop with a latency of 6–8 mo in K14cre;Brca1F/F;p53F/F (KB1P) or K14cre;Brca2F/F;p53F/F (KB2P) genetically engineered
mouse models (GEMMs). Retransplantation of spontaneous tumors in syngeneic FVB wild-type mice highlighted intertumor het-
erogeneity in treatment response. In the case of olaparib, some tumors displayed intrinsic resistance, whereas others displayed initial
good response followed by the emergence of acquired resistance. In contrast, resistance never developed in cisplatin-treated animals,
despite multiple consecutive rounds of treatment (indicated by black arrows).
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HR in BRCA1-deficient cells, including RIF1 (Chapman
et al. 2013; Di Virgilio et al. 2013; Escribano-Diaz et
al. 2013; Zimmermann et al. 2013), PTIP (Callen et al.
2013), Artemis (Wang et al. 2014), and REV7/MAD2L2
(Boersma et al. 2015; Xu et al. 2015). Thorough analysis
of mutational status and expression levels of 53BP1 and
REV7 in PARPi-resistant KB1P(M) tumors confirmed
that loss of 53BP1 or REV7 causes in vivo resistance to
PARPi (Jaspers et al. 2013; Xu et al. 2015). Interestingly,
although KB1P(M) tumors with 53BP1 loss are cross-
resistant to topotecan and doxorubicin, they are still re-
sponsive to cisplatin, suggesting that platinum drugs may
be a useful salvage therapy for this class of PARPi-resis-
tant tumors (Jaspers et al. 2013).
Although the majority of KB1P(M) tumors acquired
PARPi resistance through restoration of HR, a substantial
fraction of PARPi-resistant tumors remained defective in
the formation of ionizing radiation-induced nuclear
RAD51 foci (RAD51-IRIFs), which are a hallmark of
HR. Moreover, when we analyzed the BRCA2-deficient
KB2P tumors with acquired PARPi resistance, none of
these showed restoration of HR as measured by RAD51-
IRIF assays (E Gogola, et al., in prep.). This suggests the
existence of alternative resistance mechanisms. It was
recently shown that chemoresistance in BRCA2-deficient
cells might be mediated through protection of replication
forks (RFs)—for instance, by depletion of PAX transcrip-
tion activation domain interacting protein (PTIP) (Chaud-
huri et al. 2016). It will be important to investigate
whether RF protection is a common feature of PARPi-
resistant KB1P(M) and KB2P tumors.
In patients, mutated BRCA1 or BRCA2 proteins are
often still expressed in tumors. Therefore, the large intra-
genic Brca1/2 deletions present in KB1P(M) and KB2P
tumors—although instrumental in genetic studies—
might not fully recapitulate the biology of BRCA-associ-
ated tumors in mutation carriers. To this end, we gener-
ated several mouse models mimicking pathogenic
BRCA1 variants that are often encountered in the clinic
(Drost et al. 2011, 2016). These models provided evi-
dence that the type and location of the BRCA1 mutation
can have significant implications for the response of these
tumors to DSB-inducing agents and PARPi. It was found
that tumor cells harboring the BRCA1185delAG allelic var-
iant, which was modeled in mice by a Brca1185stop allele,
can use a downstream alternative start site leading to the
expression of a RING-less BRCA1 protein (Drost et al.
2016). This RING-less BRCA1 protein maintains hypo-
morphic HR activity, which is sufficient to induce a poor
response to platinum drugs or olaparib. These results il-
lustrate the importance of testing BRCA1 allelic variants
not only for genetic counseling but also for providing
adequate treatment.
PDX models provide a solution to narrow the gap be-
tween mouse and human cancer biology and as such rep-
resent a novel in vivo platform for studying therapy
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Figure 2. Overview of resistance mechanisms identified using mouse models of breast cancer gene (BRCA)-deficient breast cancer.
(A) Up-regulation of drug efflux pumps (i.e., MDR1) reduces intracellular drug concentration. (B) The DNA damage response pathway
can be rewired to restore homologous recombination (HR), in this case by loss of 53BP1. (C ) Genetic reactivation of BRCA1-mutated
alleles can occur because of alternative splicing, retromutations, or secondary mutations restoring the BRCA1 reading frame. (D)
Transcription of silenced BRCA1 alleles can be restored upon promoter demethylation or gene fusions to distant promoters. P-gp, P-
glycoprotein; DSB, double-strand break; NHEJ, nonhomologous end joining; HR, homologous recombination.
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response and resistance. Although PDX models have
been relatively difficult to generate in the past, recent
advances have made it possible to generate PDX bio-
banks covering a heterogeneous population of tumors
(Hidalgo et al. 2014). Once the (epi)genetic landscape
of a PDX model is characterized, this provides an effec-
tive tool to study the drug response of a specific tumor
and to predict which resistance mechanisms might evolve
during treatment. We recently demonstrated the feasibil-
ity of such an approach by treatment of PDX models of
BRCA1-deficient breast cancer with alkylating agents or
olaparib (Ter Brugge et al. 2016). Similar to the GEMM
tumors, these PDX tumors generally responded well to
treatment, but eventually developed resistance. The un-
derlying mechanism was dependent on the type of
BRCA1 inactivation: Whereas therapy-resistant BRCA1-
methylated PDX tumors frequently showed BRCA1 pro-
moter demethylation, BRCA1-mutated tumors acquired
resistance via genetic reversion through secondary muta-
tions that restored the BRCA1 reading frame (Fig. 2C,D).
These events have also been known to mediate resistance
in ovarian cancer patients (Swisher et al. 2008; Patch
et al. 2015), showing the predictive potential of PDX
models. The PDX models also revealed a novel resistance
mechanism involving gene fusions that placed BRCA1
under transcriptional control of a heterologous promoter.
It is intriguing that resistance mechanisms in PDX tumors
are mainly centered on re-expression of functional
BRCA1 protein rather than inactivation of 53BP1 or re-
lated factors, highlighting the strong selective pressure on
complete restoration of BRCA1 function when BRCA1-
deficient tumor cells are exposed to DSB-inducing ther-
apy. However, a fraction of tumors acquired resistance in
the absence of BRCA1 reexpression, showing that alter-
native resistance mechanisms also occur in PDX models.
Taken together, these studies illustrate the power of
mouse models in unraveling resistance mechanisms be-
fore their emergence in patients. It will be important to
investigate to what extent these play a role in the clinic.
This is not trivial, as they likely occur in a limited group
of BRCA patients and thus require careful patient selec-
tion. It is noteworthy that resistance caused by mutations
in additional DNA repair genes such as 53BP1 or REV7
might expose new treatment vulnerabilities (e.g., sensi-
tivity to combined PARP and ataxia telangiectasia mutat-
ed [ATM] inhibition [Bunting et al. 2010]). It will
therefore be important to determine if and how each re-
sistance mechanism can be exploited therapeutically. Ul-
timately, this may provide a framework for oncologists to
combat resistance in the clinic.
NONGERMLINE GEMMs OF
BREAST CANCER
Large-scale cancer genome sequencing studies and for-
ward genetic screens have jointly boosted the discrimina-
tion between passenger and driver mutations and the
identification of genetic determinants of drug sensitivity
and resistance in breast cancer. The systematic translation
of these long catalogs of structural aberrations into func-
tional information requires the assessment of the patho-
physiological impact of candidate gene perturbations in
reliable preclinical models. This inevitably poses a prac-
tical challenge for in vivo validation experiments, because
of the considerable costs and time requirements associated
with establishing new breast cancer GEMMs. Novel tech-
nologies, especially CRISPR–Cas9-based methods, are
revolutionizing the genetic engineering field by providing
fast ways for precise and efficient ESC manipulation and
GEMM development (Wang et al. 2013). However, as
sequencing expenses of human tumors keep decreasing,
research will shift from testing oncogenicity of single
driver alleles to investigating the impact of multiple allelic
variants on tumor development and therapy response. At
the same time, forward genetics strategies will evolve
from genome-wide approaches based on simple gene (in)-
activation to more refined chemical mutagenesis and
gene-based CRISPR screens capable of identifying novel
hypomorphic, dominant-negative, and separation-of-
function mutants at the base pair level. We foresee that
the number of testable hypotheses will far exceed the
capacity of transgenic facilities, warranting the develop-
ment of new in vivo platforms for systematic, multiplexed
interrogation of putative cancer drivers. Ideally, such
models should sort out current temporal and economical
limitations of GEMM establishment and bypass extensive
mouse husbandry but also allow a high degree of manip-
ulability and flexibility by enabling spatiotemporal con-
trol of tumor initiation and progression.
To develop such a platform for breast cancer, we ex-
plored the possibility of nongermline modeling of mam-
mary tumors by exploiting intraductal injection in the
nipple of adult female mice as a way to deliver high-titer
lentiviral or adenoviral preparations to mammary epithe-
lium and achieve somatic genome engineering. We have
shown that intraductally injected lentiviruses can target
tumor-initiating cells of both the basal and the luminal
compartment, allowing modeling of both ILC and basal-
like tumors in mice with the corresponding set of relevant
predisposing alleles. For example, intraductal injection of
Cre-encoding lentiviruses in Cdh1F/F;PtenF/F mice in-
duced the formation of ILCs that were undistinguishable
from the ILCs arising in the original WAPcre;Cdh1F/F;
PtenF/F model (Annunziato et al. 2016). Somatic Cre
delivery may more accurately recapitulate sporadic tumor
initiation by allowing titratable and spatiotemporally con-
trolled delivery of viruses to mammary tissue. Moreover,
targeting specificity can be modulated by using viruses
with cell type–specific promoters and/or posttranscrip-
tional control elements (Tao et al. 2014).
Importantly, the potential of nongermline modeling ex-
tends far beyond simple exogenous administration of Cre
to established GEMMs. A diverse array of viral and non-
viral constructs can be employed to achieve desired per-
mutations of specific candidate genes even in the absence
of germline conditional alleles: (a) vectors for overexpres-
sion of wild-type, truncated, or mutated cDNAs; (b) vec-
tors for shRNA-mediated down-regulation or CRISPR-
mediated (epi)genetic manipulation of single or multiple
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endogenous genes (Sander and Joung 2014); (c) CRISPR
vectors for modeling large chromosomal rearrangements
(Maddalo et al. 2014); and (d) vectors for tagging and
imaging of tumors (Fig. 3). Regarding CRISPR-based in
vivo editing approaches, we and others have shown that
somatic delivery of the bacterial Cas9 protein has the con-
siderable drawback of eliciting strong and specific im-
mune responses in immunocompetent animals (Wang
et al. 2015; Annunziato et al. 2016). This problem can
be overcome by employing knock-in models that are tol-
erant to Cas9 because of constitutive or conditional ex-
pression of Cas9 or catalytically inactive dCas9-effector
fusions (which allow for transcriptional silencing/activa-
tion of endogenous alleles) (Platt et al. 2014; Sa´nchez-
Rivera and Jacks 2015). We have recently reported
somatic induction of oncogenic loss-of-function muta-
tions in mice with mammary-specific expression of
Cas9 by intraductal injection of single-guide RNA
(sgRNA)-encoding lentiviruses, which eventually led to
ILC formation (Annunziato et al. 2016).
MAMMARY TUMOR ORGANOIDS
Another exciting technological breakthrough came
from the possibility to derive organotypic 3D culture mod-
els of normal and malignant mammary tissue. Human and
murine tumor organoid cultures retain key features of
donor tumors, including cellular heterogeneity and mo-
lecular characteristics (Clevers 2016; Fatehullah et al.
2016). Compared to the laborious and time-consuming
establishment of 2D cell lines, which requires adaptation
to monolayer growth on plastic surfaces, tumor organoid
cultures are much easier to derive, can be expanded indef-
initely ex vivo, and upon xenografting/allografting under-
go polyclonal expansion and efficiently produce tumors
that preserve the cellular heterogeneity and drug response
profiles of the original tumors (AA Duarte, E Gogola,
N Sachs, et al., in prep.). For example, we found the dif-
ferential olaparib sensitivity of isogenic treatment-naı¨ve
and PARPi-resistant KB1P mammary tumors to be stable
upon organoid derivation and subsequent retransplanta-
tion. Using CRISPR–Cas9 technology, we were able to
introduce Trp53bp1 frameshift mutations in the treat-
ment-naı¨ve KB1P organoid line and demonstrate that
this permutation rendered the organoid-derived tumors
refractory to olaparib. We are exploiting the KB1P tumor
organoid platform to test additional candidate drug resis-
tance genes for their in vivo relevance, including candi-
dates retrieved from forward genetic screens and from
sequencing of drug-resistant tumors (Fig. 4). Moreover,
Intraductal injections
CRISPR manipulation
of a gene
(e.g., sgPten)
CRISPR manipulation
of multiple genes
(e.g., sgPten/sgp53)
CRISPR modeling of large
chromosomal rearrangements
shRNA-mediated
downregulation of a gene
(e.g., shPten) Tagging/imaging
nascent tumors
Somatic Cre delivery
for ILC modeling
(e.g., to EcadF/F;PtenF/F)
In vivo screens for
novel TSG/oncogenes
Somatic Cre delivery
for TNBC modeling
(e.g., to Brca1F/F;p53F/F)
Study metastasis 
formation after primary
tumor removal
Overexpression of
oncogenic cDNAs
(e.g., p53 mutants)
Figure 3. Multiple applications for somatic genome engineering of the mammary tissue via intraductal injection to study tumor
biology. ILC, invasive lobular carcinoma; TNBC, triple-negative breast cancer; sgPten, single-guide phosphatase and tensin homolog;
shPTEN, short-hairpin phosphatase and tensin homolog; TSG, tumor suppressor gene.
1-2 weeks
3D tumor organoid
derivation and modification
GEMM/PDX tumor Modified isogenic
GEMM/PDX tumor
2-3 weeks1-2 weeks
Figure 4. 3D tumor organoid cultures can be rapidly derived from established genetically engineered mouse model (GEMM)/patient-
derived xenograft (PDX) tumors, modified ex vivo with desired genetic permutations and retransplanted in mice to evaluate in vivo
treatment responses.
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given the short latency period and polyclonal tumor out-
growth, GEMM and PDX tumor organoids are particular-
ly amenable for in vivo genetic screens using short-hairpin
RNA (shRNA), CRISPR, CRISPRi, and CRISPRa
libraries.
CONCLUSION
A number of known and unknown biological discrep-
ancies inevitably exist between mouse models and hu-
mans. Moreover, refinements in mouse modeling should
be compliant with practical and ethical issues associated
with model establishment. Nevertheless, the systematic
and synergistic deployment of complementary in vitro
and in vivo platforms (GEMMs, PDX models, organo-
ids, nongermline models) is envisioned to provide a
quantum leap in the oncology arena and in breast cancer
research in particular. Cutting-edge mouse cancer clin-
ics will enable so-called coclinical trials, in which clin-
ical studies will be paralleled by preclinical intervention
studies in mouse avatars. This will allow clinicians to
infer in real-time genotype-specific drug response pro-
files from mouse models and design more effective and
long-lasting patient-tailored treatment schemes. The
emergence of drug resistance is an invariable and intrin-
sic consequence of Darwinian tumor growth dynamics,
but instead of “whack-a-mole” treatment schedules,
coclinical trials could assist in the design of more so-
phisticated and personalized regimens in which tumors
are forced through evolutionary bottlenecks that render
them exquisitely sensitive to secondary therapies. Reit-
eration of this adaptive process is possible only by the
use of ever-smarter mouse models, which will ultimate-
ly lead to improved long-term management of this dev-
astating disease.
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